Data solutions provider TARGET PharmaSolutions has commenced a large-scale observational trial called TARGET-DERM to obtain real-world evidence for immune-mediated inflammatory skin conditions (IMISCs).

TARGET-DERM will initially focus on atopic dermatitis (AD/eczema). Its design is disease-focused rather than treatment-specific, for enabling capture of natural history and outcomes data continuously.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will gather retrospective and prospective data over three years and five years, respectively, on a total of up to 15,000 adult and paediatric patients at about 100 sites across the US.

The collected data is set to include patient reported outcomes (PROs), with new therapies entering the market and clinical programmes evolving.

This data will be made available on a biorepository that can be accessed by TARGET-DERM stakeholders for genomic studies and translational research.

In addition, the trial will develop a research registry of IMISCs patients within academic and community real-world practices. The registry is intended to study the safety and effectiveness of existing as well as future therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Icahn School of Medicine dermatology department vice-chair Emma Guttman-Yassky said: “TARGET-DERM is a unique opportunity to better understand the natural history of AD and other diseases and to evaluate different treatment regimens, outcomes and adverse events across a large, diverse patient population.

“It is our hope that this research can better inform how these conditions are approached and ultimately improve the lives of the millions of people who suffer from them.”

Guttman-Yassky is part of an academic steering committee that will lead the observational trial.

In the future, the trial will be expanded to additional skin conditions – hidradenitis suppurativa, alopecia areata and vitiligo.